MedTrace Logo

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

NCT04412096 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2026-03-04

No results posted yet for this study

Summary

Glaucoma is a major cause of blindness. The inability to predict a patient's IOP response to medications is a critical barrier for the clinician to consistently provide highly effective IOP-based treatments. Current trial-and-error approaches to glaucoma management are inefficient and have not addressed this barrier as there are no predictive factors for drug response. Our long-term goal is to improve outcomes by identifying biomarkers and environmental factors that profile a patient at risk for glaucoma by age-of-onset, rate of disease progression, "poor response" to treatment, and large IOP fluctuation. Our purpose of this research project is to address this critical barrier by focusing on physiological factors that predict IOP response to drugs.

Conditions

Interventions

DRUG

Timolol 0.5% ophthalmic solution

1 drop BID

DRUG

Latanoprost 0.005% Ophthalmic Solution

1 drop QD

Sponsors & Collaborators

  • University of Nebraska

    collaborator OTHER

  • National Eye Institute (NEI)

    collaborator NIH

  • Mayo Clinic

    collaborator OTHER

  • Ohio State University

    lead OTHER

Principal Investigators

  • Sayoko Moroi, MD, PhD · Professor and Chair

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-23
Primary Completion
2025-05-22
Completion
2025-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04412096 on ClinicalTrials.gov